Surgeries & Interventions

Medtronic’s Symplicity Spyral RDN System Lands FDA Approval

The brand new US renal denervation arena gained its second major competitor on Friday, with the FDA approval and immediate commercial launch of Medtronic’s Symplicity Spyral RDN system.

  • Renal denervation (RDN) is intended for hypertension that can’t be controlled by conventional therapies, either due to ineffectiveness, side effects, or adherence issues
  • RDN is a minimally invasive procedure that lowers blood pressure by denervating the sympathetic nerves surrounding renal arteries, reducing overactivity that can lead to hypertension
  • Medtronic’s Symplicity Spyral RDN system has been in development for 14 years, and is already approved in over 70 countries globally

The Symplicity Spyral’s approval comes just 10 days after Recor Medical’s Paradise system became the first RDN system to land FDA approval, suddenly introducing two RDN systems to US clinicians and patients who were limited to pharma and lifestyle interventions before now.

The approval also represents somewhat of a comeback story, after an FDA expert panel voted against the Symplicity Spyral in August, finding that its benefits didn’t outweigh its risks (6-7 vote).

  • Recor’s RDN system on the other hand, came away with a panel endorsement through a far stronger 10-to-2 vote

It’s possible that the Symplicity Spyral’s approval was helped by an updated FDA indication, positioning it as an “adjunctive treatment (aka additional treatment) in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”

  • That’s the same FDA indication as the Recor Paradise system, but represents a change from Medtronic’s PMA application which didn’t limit the Symplicity Spyral to patients also taking antihypertensives (not just for adjunctive use).

With the Symplicity Spyral’s approval now complete, eyes will be on Medtronic’s powerful commercial organization to see how they can bring RDN into clinical practice, noting the many hurdles that completely new interventions usually face when targeting a disease that’s historically been treated with medications.

Takeaway

Although media coverage might focus on the Spyral Symplicity’s negative panel vote, that will only matter if it doesn’t prove effective in the clinic or for Medtronic’s business.

What might not get enough coverage is how much of a monumental feat this is for the Medtronic RDN team, and what the sudden availability of two different renal denervation systems might mean for hypertension treatment in the US. 

If renal denervation ends up achieving what Medtronic and Recor believe it’s capable of, we just entered a completely new era in hypertension treatment.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Heart Failure October 20, 2025

Don’t Blame Your Heart for Heart Failure October 20, 2025

Perhaps the biggest cardiology story of the year, an entire issue of JACC now hypothesizes that heart failure with preserved ejection fraction (HFpEF) might actually be caused by visceral fat tissue that triggers cardiac weakening through adipokine signaling. The new unifying adiposity framework now proposes that visceral fat expansion causes secretion of an altered adipokine […]

Cardiology Business October 16, 2025

MedAxiom Report: Cardiologist Compensation Soars, Patient Access Struggles October 16, 2025

Good news and bad news from MedAxiom’s latest cardiology compensation survey. The good news? Cardiologist median compensation reached new record highs last year. The bad news? Patient access deteriorated while the number of patients physicians had to manage swelled. The 2025 survey findings aggregated data across cardiology, cardiac surgery, and vascular surgery specialties, examining compensation […]

Heart Failure October 13, 2025

Specialist Care Can Improve HF Outcomes Across the Board October 13, 2025

A recent study out of the U.K. suggests that multidisciplinary team management could significantly reduce death or rehospitalization risk for HF patients across the LVEF spectrum. Based in a single U.K. county, the Buckinghamshire analysis examined 2.1k patients hospitalized for acute heart failure who received either specialist care or standard care over a 618-day follow-up […]